China NMPA Legal Agent Services

The NMPA Legal Agent is the local authorized representative for any MedTech and IVD manufacturer located outside China. The NMPA* Legal Agent must be a Chinese entity. Just as for submissions in Europe and US, all dossier or product approval submissions to Chinese authorities must be made by the China Agent.

*NMPA stands for the National Medical Products Administration, which is China’s regulatory authority responsible for medical devices.

The official name of the authorized representative role is expected to change from Legal Agent to Domestic Responsible Agent. This was proposed in the draft Medical Device Law which is set to replace the current regulation Order 739. The draft was released in draft format for public comment on August 26, 2024.

Selecting the most appropriate form of Chinese local representation is an important early step in the filing or registration process for your medical device, together with choosing the right agent to ensure compliance and proper representation.

Cisema - your China in country agent
China agent

There are 3 broad categories of local representative available to overseas companies:

1

Choosing a Local Distributor

2

Setting Up a Chinese Subsidiary
or Legal Entity

3

Appointing an Independent 
Service Provider

Cisema Acts as an Independent Service Provider of Services for a Growing Number of Companies

Below we set out the advantages and setbacks of each option:

Distributor

Distributor may offer to cover upfront investment required to register in return for lower transfer price
Possible IP violation as the Distributor has access to sensitive information as part of the registration process
Distributor retains control of registration certificates which can impact imports, change notifications and renewals
No other Distributor can be added without their approval; it can also be difficult to replace Distributor

Own Subsidiary

Retain full control of certificates and therefore flexibility in choosing as many channel partners as required
Requires an established and well-functioning Post-Market Surveillance system in China to conform with NMPA requirements
Considerable investment required to set up a company, find and hire qualified and experienced regulatory experts

Distributor

Qualified and experienced regulatory and quality experts available immediately to register your product and undertake Post-Market Surveillance
Retain full flexibility in choosing or replacing channel partners as required
Retain full control of certificates
Annual representation fees/costs

Role of a China Agent

A China Agent plays a crucial role in applying for medical device and IVD filings and registrations. Acting as the official representative for the foreign companies, the agent is responsible for submitting applications, communicating with the NMPA, and ensuring that all regulatory requirements are met.

This role demands a deep understanding of the Chinese regulatory framework and mandates that the agent be a Chinese legal entity.

By navigating the complexities of the regulatory landscape, the in country representative ensures that the foreign manufacturer’s products comply with local laws, facilitating a smoother entry into the Chinese market.

Role of a China Agent

Responsibilities of an NMPA Legal Agent

They play a critical role throughout the entire product registration process and product lifecycle in China. Acting on behalf of the overseas manufacturer, the legal agent ensures full compliance with relevant regulations issued by the NMPA and the State Council. This includes submitting and maintaining the registration application, managing communications with authorities, and holding a valid business license in China.

The agent is also responsible for adverse event reporting and monitoring, ensuring timely updates and transparency in line with Chinese requirements. They help implement product traceability and an effective recall system to maintain product quality and safeguard public health.

In addition, the legal agent must keep the original NMPA certificate, inform the authorities of any change in the legal manufacturer or appointment of a new agent, and support ongoing regulatory compliance. Their support enables the overseas manufacturer and their Chinese distributor or sales agents to focus on business growth while maintaining regulatory alignment in the country.

Can I Change My Agent?

Yes, changing your Chinese Agent is possible. Manufacturers often consider this when dissatisfied with their current agent, especially if the agent is also their distributor. In such cases, appointing an independent agent like Cisema can provide greater transparency and control.

The process typically takes around seven weeks and requires a copy of the NMPA registration certificate and the Product Technical Requirements (PTR). Obtaining these documents from distributors who handled the original application can sometimes be challenging, but we’re here to help you overcome this hurdle—reach out to us if you're facing this situation.

Can I Become My Own Agent in the Future?

Yes, this is quite common for companies which shift to manufacturing in China. A foreign manufacturer that sets up an organization in China can, in principle, act as their own agent. This local company must satisfy the NMPA's regulatory requirements and is legally responsible for compliance during the entire product life cycle - which includes product registration, post market surveillance, and communication with authorities.

Cisema can remain contracted to assist with communications and post-market surveillance, while some businesses look to adopt this responsibility themselves once local operations are properly set up. Taking on these operational duties in-house allows for greater oversight, but it does mean hiring resources to understand the regulatory framework within China and its changes.

If you’re planning to manufacture in China and wish to eventually act as your own Legal Agent, we can assist in facilitating a seamless transition—feel free to reach out for guidance.

Adverse events

Our China NMPA Legal Agent Services

As your local authorized representative in China, we are your single point of contact for all NMPA matters. As we are independent of any distributor, we ensure that you maintain control of your product registrations and retain an unconstrained choice of your market access partner(s), giving you full flexibility to adapt as necessary to changes in the market.

Our services include:

Prepare, Submit & Follow Up Applications to the NMPA:

NMPA Online Account
Filings & registrations
Change & product extension
Change of local authorized representative
Class II & III renewals
Advertisement approval
Medical Insurance Code
UDI

Regulatory & Quality Assurance Support for “Made in China” Certification Including:

Acting as your MAH
QMS gap analysis & adaptation
CMO pre-audit and assistance
Post-Market Surveillance & auditing of CMO 

Other Services Include:

Provide regulatory & standards updates and news related to your filings & registrations 
Review of Chinese names, labels & IFUs 
Cooperate with regulatory authorities for market supervision and inspection activities. 
Customs clearance & tender bidding support 

Request a Proposal from our Life Sciences Team about Appointing us or Changing your Agent to Cisema

Let Cisema help turn your plans into reality.

Request Proposal

Useful Articles

View More

Understanding Local Testing for Medical Devices & IVDs in Indonesia: Requirements & Registration Guide

Learn when local testing is required for medical devices and IVDs in Indonesia, which products are affected, and how testing impacts registration requirements.

August 31, 2026
Understanding Local Testing for Medical Devices & IVDs in Indonesia: Requirements & Registration Guide
An Indonesian male medical professional in profile, wearing dark blue scrubs, a blue surgical cap, safety glasses, a white mask, and a blue-tubed stethoscope, presses a button on a dual-monitor medical control panel in a clinical operating setting.

China Medical Device GMP vs ISO 13485: Key Differences Explained

Understand the key differences between China Medical Device GMP and ISO 13485, including requirements for quality management, suppliers, facilities and documentation.

August 26, 2026
China Medical Device GMP vs ISO 13485: Key Differences Explained
Two Chinese medical device technicians, a woman and a man wearing white lab coats, surgical caps, face masks, and protective gloves, stand side by side in a sterile cleanroom environment.

5-Step Guide to Taiwan Medical Device Classification (TFDA)

How to determine medical device classification in Taiwan: the TFDA catalogue, the 16 categories, Class I-III risk levels, and what to do when no item matches.

August 21, 2026
5-Step Guide to Taiwan Medical Device Classification (TFDA)

Guide to Indonesia Medical Device Post-Registration Changes: Notification, Variation, or New Registration

Learn when medical device and IVD changes in Indonesia require a notification, variation, or new registration, and how to maintain ongoing regulatory compliance.

August 5, 2026
Guide to Indonesia Medical Device Post-Registration Changes: Notification, Variation, or New Registration

How Vietnam Medical Device Registration Works (Timelines, Fees, & AR Strategy)

Gain an overview of the medical device registration process in Vietnam with timelines, fees, and Authorized Representative requirements.

August 4, 2026
How Vietnam Medical Device Registration Works (Timelines, Fees, & AR Strategy)

Understanding the ASEAN Medical Device Market: Comparing 6 Strategic Markets

Explore the medical device market opportunities, regulations, and registration pathways across Malaysia, Singapore, Vietnam, and other key ASEAN countries.

August 4, 2026
Understanding the ASEAN Medical Device Market: Comparing 6 Strategic Markets
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive.

China Medical Device Registration

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.

Learn more

NMPA Type Testing

We provide end-to-end support for China type testing in NMPA-accredited laboratories. Our experienced test engineers offer on-site supervision to guarantee accurate and reliable results.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

NMPA Clinical Evaluation Report

CERs can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.

Learn more

Drug Device Combination Products

We assist with the classification, registration, and compliance of combination products in China, whether drug or device led.

Learn more

China Medical Device Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.

Learn more

Medical Device PMS & Vigilance

The NMPA is placing greater focus on Post-Market Surveillance (PMS) such as more in-market sampling inspections and regular standard changes.

Learn more

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

Learn more

Latest Insights

View More

Malaysia NPRA Updates Cosmetic Ingredient Requirements Under the ASEAN Cosmetic Directive

Circular No. 2/2026 revises prohibited, restricted, colorant, and preservative requirements for cosmetics marketed in Malaysia.

August 20, 2026
Malaysia NPRA Updates Cosmetic Ingredient Requirements Under the ASEAN Cosmetic Directive

China Overhauls Cosmetic Safety Rules with GB 7916-2026: Is Your Brand Ready?

Brands must audit ingredients, suppliers and packaging before January 2028 to ensure compliance with GB 7916-2026.

August 18, 2026
China Overhauls Cosmetic Safety Rules with GB 7916-2026: Is Your Brand Ready?
Scientist in clean modern room inspects cosmetics.

China Expands Animal Testing Data Exemptions in Major Cosmetics Registration and Filing Reform

Companies can benefit from expanded toxicology data exemptions, simplified cosmetics registration procedures, and more efficient compliance pathways

August 18, 2026
China Expands Animal Testing Data Exemptions in Major Cosmetics Registration and Filing Reform

Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites

As of July 1, 2026, Taiwan has completed its cosmetic GMP rollout, extending mandatory ISO 22716-based manufacturing standards to nearly all cosmetic factories

August 18, 2026
Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites

China Updates New Cosmetic Ingredient Registration Rules: Several Higher-Risk Ingredient Categories Removed

New NCI rules reduce administrative burden, streamline dossiers, and expand opportunities to reuse existing safety data.

August 18, 2026
China Updates New Cosmetic Ingredient Registration Rules: Several Higher-Risk Ingredient Categories Removed
This stock photo features a close-up, high-angle shot focusing on a skincare product arrangement set against a light-colored, wood-grain surface.

NMPA Opens Consultation on Two Draft Cosmetic Adverse Reaction Standards: Cosmetic Cheilitis & Cosmetic Contact Urticaria

Review China's new draft standards for cosmetic cheilitis and contact urticaria before the August 15, 2026, consultation deadline.

August 18, 2026
NMPA Opens Consultation on Two Draft Cosmetic Adverse Reaction Standards: Cosmetic Cheilitis & Cosmetic Contact Urticaria
Previous
Previous

Ready to Navigate Complexity & Achieve Success in China & Asia Pacific?

Let Cisema help turn your plans into reality.

Request Proposal